22 NOVEMBER

Expedited Timeframes and Exceeded Targets for COVID-19 Diagnostic Trial

Expedited Timeframes and Exceeded Targets for COVID-19 Diagnostic Trial

With the pandemic still overrunning most of the world, New Zealand’s management of the spread and its support of COVID-19 related clinical trials has made it an ideal location for these studies.

There is an urgent need for organisations to develop COVID-19 vaccines, treatments, and improved diagnostic tests and for these to be tested and rolled out to the public safely but quickly.

As PharmaSols has developed a reputation for successful rapid study start-ups and being uniquely positioned in New Zealand, we were engaged by an organisation looking to run a clinical trial for a COVID-19 diagnostic test. It was imperative that this study be carried out without costly interruptions (such as the pandemic has known to cause in other parts of the world) and needed to be handled by a CRO that could manage tight timeframes.

Having a proven record of flexible and rapid solutions, PharmaSols were the ideal CRO partner selected to take on this challenge.

  

Challenges

There were several challenges while supporting this study:

  • Tight timelines across participant recruitment
  • Urgency for the product
  • Need for rapid ethics and regulatory approval

 

COVID-19 and New Zealand

The New Zealand government has long recognised the importance of clinical trials and has allowed them to run as essential services throughout varying lockdown alert levels.

In addition to this, New Zealand has expedited ethics and regulatory processes for COVID-19 related trials. As this trial concerned the development of a COVID-19 diagnostic test, PharmaSols was able to achieve rapid E&R approval.

As soon as PharmaSols received the protocol, the first submission was made in just three working days. Within one day of receiving provisional approval, we resubmitted with some amendments to the protocol as per the ethics committee’s recommendations.

The ethics committee fully approved this, just 12 working days after the second submission.

 

Recruitment success

While patient recruitment is a consistent pain point in the clinical trial journey, PharmaSols has established networks and a patient-centric attitude which helps us achieved patient recruitment targets.

As there has been relatively low rates of COVID-19 transmission in New Zealand, the population is more inclined to participate in studies. Along with that, PharmaSols recognises the value of building processes based on a patient-centric attitude. Having a people-driven team and collaborative networks within the industry aids us in delivering participant recruitment and retention targets.

The timeline from first SIV to first participant first visit was accomplished by PharmaSols in only 5 days. We were able to exceed the original participant target within only a 9 day recruitment period.

New Zealand entered into its second month of lockdown during the recruitment period, as the delta variant had made its way into the country in the previous weeks. Despite this, we were still able to carry out our recruitment process as normal and overachieved our target. 

 

Outcome

In all, PharmaSols received ethics and regulatory approval in only 21 days from receiving the protocol.

Not only was our team able to leverage New Zealand’s unique position to receive rapid ethics and regulatory approval for this study, but we were also able to recruit 101% of the original patient target in just over a week.

PharmaSols continues to work towards delivering exemplary results like this while providing high-quality and people-driven dedication.

Case Studies

Patient Recruitment Targets Exceeded for COVID-19 Vaccine Trial

Due to PharmaSols unique location and history of successful rapid start-ups, we were engaged by a European specialty vaccine company running a COVID-19 vaccine study. This study needed to be conducted without interruptions caused by the virus itself and with a CRO that could handle tight recruitment timeframes.

Read more
Expedited Timelines and Recruitment Success for COVID-19 Vaccine Trial

While the pandemic has slowed down most of the globe, it has increased the demand for rapid solutions within the pharmaceutical industry, with an urgent need to find a vaccine and COVID-19 related treatments and vaccines. Running clinical trials for potential solutions is a vital element in this process.

Read more
Exceeding Site Identification Targets Across Three Recent Clinical Trial Studies

Site identification is the first and most critical deliverable from a CRO. Without an appropriate site, there is no patient recruitment, and without patients, there is no study.

Read more
High Recruitment: Twice as many patients as global CRO

Faced with a challenging recruitment process, needing to recruit a large number of elderly participants within a tight three-month seasonal recruitment window, a US-based Biotech Company appointed PharmaSols as the NZ CRO for this phase three respiratory clinical trial.

Read more
Rapid start-up: First SIV in less than 35 days

Having previously worked with PharmaSols over a number of trials, the US sponsor knew that the PharmaSols team could deliver on both tight start-up timelines and high recruitment targets. PharmaSols proven record of flexible, rapid, and creative solutions meant we were the ideal CRO partner.

Read more
Creative Solutions for US Biotech Clinical Trial

A US-based Biotech company was seeking a CRO who could successfully recruit a large number of elderly research participants in New Zealand. A challenge that was not only squeezed into a three-month seasonal recruitment window but was also met with issues so unique, there were no established protocols.

Read more
Rapid Start-up and Tight FPI Timeline for US Biotech Clinical Trial

After a sudden decision to expedite their study timelines, a US Biotech company approached PharmaSols in need of a CRO who could successfully achieve a quality rapid start-up within a tight timeline.

Read more
Quick Feasibility for Rare Genetic Trial

A US Biotech company reached out to PharmaSols, to investigate the feasibility of running a trial in New Zealand on participants' stored tissue samples, where consent had been given for further research to identify a rare genetic marker.

Read more